Official websites use .gov
Secure .gov websites use HTTPS
« Previous
Next »
Titles
- A comparison of brand-name drug prices among selected federal programs1
- Applying a premium cap in Medicare Part B and Part D1
- Capping Medicare beneficiary Part D spending at $2,000: who would it help and how much?1
- Catastrophic coverage in the Medicare Part D drug benefit: which beneficiaries need it and how much are they spending?1
- Closing the "doughnut hole" has helped protect millions of Medicare beneficiaries from high drug costs1
- Do states adjust Medicaid enrollment in response to capitation rates?: evidence from the Medicare Part D clawback1
- Does Medicare Part D protect the elderly from financial risk?1
- Drug price increases that exceed inflation are costing Medicare Part D billions1
- High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia1
- High-expenditure Medicare drugs often qualified for Orphan Drug Act incentives designed to encourage the development of treatments for rare diseases1
- How much does out-of-pocket medical spending eat away at retirement income?1
- How will the Medicare Part D benefit change under current law and leading proposals?1
- Increases in reimbursement for brand-name drugs in Part D1
- Medicare Part D2
- Medicare Part D and beneficiaries could realize significant spending reductions with increased biosimilar use1
- Medicare Part D and the financial protection of the elderly1
- Medicare Part D enrollee out-of-pocket spending: recent trends and projected impacts of the Inflation Reduction Act1
- Medicare Part D enrollee savings from elimination of vaccine cost-sharing1
- Medicare Part D: CMS should monitor effects of rebates on drug coverage and spending : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives1
- Medicare Part D: CMS should monitor effects of rebates on plan formularies and beneficiary spending : report to congressional requesters1